14
FEB
2011

Northwest Biotherapeutics To Present At BIO CEO & Investor Conference

Posted By :
Comments : Off
Highlights Include Clinical and Corporate Updates, Striking Long-Term Data, and Lack of Toxicity, Low Cost and Simplicity of DCVax® Therapeutic Vaccines Bethesda, Maryland, February 14, 2011 – Northwest Biotherapeutics (OTC Bulletin Board: NWBO) announced today that its Chair of the Board of Directors, Ms. Linda Powers, will give a corporate presentation at the 13th Annual Biotechnology Industry Organization’s BIO CEO &...
Read More
24
JAN
2011

Northwest Biotherapeutics Resuming Enrollment In Promising 240-Patient Clinical Trial Of DCVax® For Brain Cancer

Posted By :
Comments : Off
Bethesda, MD, January 24, 2011 – Northwest Biotherapeutics (OTC Bulletin Board: NWBO) announced today that the Company is resuming enrollment of additional new patients into its ongoing 240-patient, double blind, randomized, placebo controlled Phase II clinical trial of DCVax® for Glioblastoma multiforme (“GBM”) brain cancer. To date, this trial has been conducted at 13 clinical sites across the U.S., with 33 patients already having...
Read More
04
NOV
2010

Northwest Biotherapeutics Receives Two “Qualified Therapeutic Discovery Project” Grants

Posted By :
Comments : Off
Bethesda, MD, November 4, 2010 – Northwest Biotherapeutics (OTC Bulletin Board: NWBO) today announced that the company has received approximately $490,000 in two grants under the Qualified Therapeutic Discovery Project Grants Program. The maximum award was received for both grants. The Therapeutic Discovery Project Grant Program was included in the healthcare reform legislation enacted last March, and established a one-time pool of $1...
Read More
14
OCT
2010

Northwest Biotherapeutics To Present At Inaugural Cancer Immunotherapy Conference

Posted By :
Comments : Off
BETHESDA, Md., Oct. 14 — Northwest Biotherapeutics (OTC Bulletin Board: NWBO) today announced that the company will be presenting at the Cancer Immunotherapy: A Long-Awaited Reality conference taking place from 8:00 a.m. to 6:00 p.m. EDT on October 21, 2010, at the New York Academy of Medicine in New York. Dr. Marnix Bosch, Chief Technical Officer, will provide an overview of the Company’s DCVax® technology and unprecedented...
Read More
03
AUG
2010

Long-Term Follow-Up Of DCVax®-Treated Brain Cancer Patients Shows 33% Of Patients Reached 4-Year Survival And 27% Have Reached Or Exceeded 6-Year Survival

Posted By :
Comments : Off
BETHESDA, MD – August 3, 2010 – Northwest Biotherapeutics, Inc. (“NWBT” or the “Company”) (OTCBB: NWBO) today announced further positive long-term follow-up data from its prior Phase I and Phase I/II clinical trials, in which patients with newly diagnosed Glioblastoma multiforme (“GBM”), the most rapid and lethal type of brain cancer, were treated with NWBT’s DCVax®-Brain personalized immune therapy. The data through July 1, 2010, show that...
Read More